Nova Sud Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 6.86 Cr
as on 16-06-2024
- Paid Up Capital ₹ 6.86 M
as on 16-06-2024
- Company Age 17 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 72.52%
(FY 2023)
- Profit -206.43%
(FY 2023)
- Ebitda -122.31%
(FY 2023)
- Net Worth -2.82%
(FY 2023)
- Total Assets -3.83%
(FY 2023)
About Nova Sud Pharmaceuticals
The Corporate was formerly known as Panindia Pharma Distributors Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.86 Cr and a paid-up capital of Rs 6.86 M, as per Ministry of Corporate Affairs (MCA) records.
Prasad Battinapatla, Satya Kammila, and Phani Ramella serve as directors at the Company.
- CIN/LLPIN
U24232TG2007PTC055895
- Company No.
055895
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Oct 2007
- Date of AGM
27 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Nova Sud Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prasad Battinapatla  | Director | 29-Sep-2021 | Current |
| Satya Kammila | Director | 29-Sep-2021 | Current |
| Phani Ramella | Director | 31-Jul-2014 | Current |
Financial Performance and Corporate Structure Insights of Nova Sud Pharmaceuticals.
Nova Sud Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 72.52% increase. The company also saw a substantial fall in profitability, with a 206.43% decrease in profit. The company's net worth dipped by a decrease of 2.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nova Sud Pharmaceuticals?
In 2023, Nova Sud Pharmaceuticals had a promoter holding of 100.00%. The company had 5 Subsidiaries and 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Sai Sridhar Pharma Private LimitedActive 17 years 2 months
Satya Kammila and Phani Ramella are mutual person
- Deccan Medisales Private LimitedActive 13 years 6 months
Satya Kammila and Phani Ramella are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nova Sud Pharmaceuticals?
Unlock and access historical data on people associated with Nova Sud Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nova Sud Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nova Sud Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
